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ity. ConClusions: FU and MW are common physical therapies for cervical ectopy. 
But the available evidence suggested that FU is more safe and effectiveness than 
MW for treating cervical ectopy and preventing STIs. However, potential publication 
bias and low quality evidence will reduce the reliability of our results. More careful 
designed studies are needed to provide further clarification.
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EffEct of VaccINatIoN agE oN cost-EffEctIVENEss of HumaN 
PaPIllomaVIrus VaccINatIoN agaINst cErVIcal caNcEr IN cHINa
Liu YJ, Zhang Q, Hu SY, Zhao FH
Chinese Academy of Medical Sciences & Peking Union Medical College, Beijing, China
objeCtives: The cost-effectiveness (CE) of human papillomavirus (HPV) vaccination 
in women pre-sexual debut has been demonstrated in many countries. The aim of 
this study is to estimate the CE of a 3-dose bivalent HPV vaccination at ages 12 to 55 
year in both rural and urban settings in China. Methods: A previously published 
Markov cohort model was adapted to the Chinese setting, simulating the natural 
history of HPV infection and including the effect of screening and HPV vaccination 
over the lifetime of a 100,000 female cohort for ages 12 to 55 in rural and urban 
China. Transition probabilities and utilities were obtained from published literature. 
Cost data were estimated by Delphi panel using health care payers’ perspective. 
Vaccine cost was assumed  Hong Kong listed price. Vaccine efficacy (VE) was based 
on the PATRICIA trial data assuming VE irrespective of HPV type at all ages on inci-
dent HPV. Costs and outcomes were discounted at 3%. Cervical cancer (CC) cases 
and incremental cost-effectiveness ratio (ICER) for vaccination and screening com-
pared with screening alone were estimated for each vaccination age. Reduced VE in 
women post-sexual debut were investigated in scenario analyses. Results: With 
70% vaccination coverage, a reduction of CC cases varying from 585 to 33 in rural and 
691 to 32 in urban were estimated at ages 12 to 55, respectively. Vaccination remains 
CE up to age 23 in rural and age 25 in urban, as the discounted ICERs were lower 
than the current threshold (3×national GDP 2013/capita=20,292USD, 125,723RMB). 
Scenario analyses with lower VE post-sexual debut confirmed the results with age 
20 in rural and 21 in urban to remain CE. ConClusions: HPV vaccination program 
in girls before age 23 in rural and 25 in urban setting was shown to be cost-effective 
strategies for the prevention of CC in China.
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objeCtives: To evaluate the cost-effectiveness of caspofungin versus C-AmB for 
empirical antifungal therapy in patients with neutropenic fever from health care 
provider perspective in Thailand. Methods: A decision-analytic model was used 
to project costs and outcomes of caspofungin versus C-AmB from treatment initia-
tion until hospital discharge. Since there has not been a head-to-head compara-
tive trial, an indirect treatment comparison was developed based on clinical trials 
that used the same 5-end point composite outcomes, including resolution of fever, 
resolution of baseline infection, absence of breakthrough infection, survival and 
no premature discontinuation. Patients were stratified by the presence or absence 
of baseline infection. Discontinuation because of nephrotoxicity or other adverse 
events were included in the model. Efficacy and safety data were based on Walsh 
2004 (Scenario I) and Walsh 1999 (Scenario II). Life expectancy, quality of life, medical 
resource utilization and disease-related costs were obtained from the literatures 
and expert opinion. Drug prices were those published by Ministry of Public Health. 
All costs were expressed in THB 2013 values. Results: Treatment with caspofungin 
increased life expectancy (LY) by 0.87 and 0.58 years, and resulted in additional 0.63 
and 0.41 quality-adjusted life years (QALYS) when compared to C-AmB in Scenario 
I and II, respectively. In the base-case, use of caspofungin was cost saving in both 
scenarios. The results showed that caspofungin is cost-saving as long as the cost 
of treating nephrotoxicity is higher than 316,830 and 299,762 THB for the respective 
scenarios. The incremental cost-effectiveness ratio (ICER) increases if the cost of 
treating nephrotoxicity or the relative rate of nephrotoxicity decreases. Probabilistic 
sensitivity analysis supported the robustness of these findings. ConClusions: 
This is the first cost-effectiveness   of caspofungin as empirical treatment in 
Thailand. Caspofungin is more effective and less costly compared to C-AmB, and 
the use of caspofungin is anticipated to have both budgetary and health benefits.
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objeCtives: To estimate the effects of maternal education and other associ-
ated factors on the immunization propensity for children and adolescents in 
China. Methods: A longitudinal survey (China Health and Nutritional Survey) 
between 1991 and 2006 were used to analyze the relationship between the immu-
nization receipt status and the potential determinants, including children’ char-
acteristics, the household’ characteristics and the community level influences. 
The recommended immunization schedule for persons aged 0 through 18 in 
China is similar to that from Centers for Disease Control and Prevention in the 
U.S. Descriptive statistics were reported for the sample from 9 provinces of China 
in each wave of surveys. Econometric models were constructed with an indicator 
for immunization propensity as the dependent variable (i.e., any immunization 
received by your children during the past 12 months). Independent variables include 
children’s age, gender, whether preventive health care services covered by insur-
ance, their parents’ education level, the household income, transportation time to 
may increase the difficulty of demonstrating cost-effectiveness of a new treat-
ment (NEW).  Conversely, anticipating generic entry for NEW may improve cost-
effectiveness, particularly if initially of high-cost.  The objective of this study was 
to quantify the impact of anticipated PD on reimbursement decision making in 
the Australian context via multi-cohort cost-effectiveness analysis. Methods: A 
two state oncology model was constructed comparing NEW to SOC over 30-years. 
Probability of survival was assumed to be 3-times higher for NEW at 150-times 
the price of SOC. A price function, based on Australian PD statistics, was applied 
to the price of NEW from year 10 to emulate generic entry.  30 cohorts were run 
through the model, each commencing in subsequent years.  ICERs for each cohort 
and an aggregate ICER across all cohorts were calculated.  Whilst no ICER thresh-
old is applied in Australia, $50k/LY was assumed for analysis purposes. Results: 
For individual cohorts, the cost-effectiveness of NEW improved over time.  ICERs 
ranged from $71K/LY for Cohort 1 to $100/LY for Cohort 22 onwards.  The threshold 
was crossed between Cohort 10 and 11.  For all cohorts over 30 years the aggregate 
ICER was $39K/LY, however only 19 cohorts were required over as many years to 
cross the threshold at an ICER of $49K/LY. ConClusions: TTraditional CEA only 
supports funding of NEW from Cohort 11 onward, suggesting a potential 10 year 
delay to access.  Aggregate CEA however supports funding of NEW immediately 
over a time-horizon of 19 or more years.  Clearly future price changes affect CEA of 
new treatments; failure to appropriately account for them may result in delayed 
access to new medications.
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objeCtives: China spent approximately $150 billion US dollars on prescription 
drugs in 2010, accounting for 47% of its annual health expenditures, which has 
attracted worldwide attention. To investigate the causes of rising drug spend-
ing in China, we decomposed drug expenditures to document reasons for this 
event. Methods: Records of 209,758 inpatients were collected from Urban 
Employee Basic Medical Insurance system covering 626 hospitals and 545 health 
care community centers from 2006 to 2010 in Tianjin, China. We found that 264 anti-
infective drug products with 79 ingredients from 16 narrow therapeutic categories 
were calculated using three and six-factor exponential analysis and index-theoret-
ical methodology. In three-factor analysis, drug expenditure was decomposed into 
quantity effect, price effect and therapeutic choice. To further explore underlying 
cause of drug spending soaring, six-factor exponential methodology was applied to 
measure the change and contribution of each dominant. Results: Using exponen-
tial-based decomposition analysis to elucidate important factors driving prescrip-
tion drugs expenditure growth (which increased 163% during five years), we found 
that quantity effect and therapeutic choice increased by 71% and 45% respectively 
and price effect increased by 6% only. Six-factor analysis revealed that 2010 inpatient 
admission volumes increased 76% and this was the most critical spending driver. 
Therapeutic mix and drug mix within the therapeutic choice was the second most 
important factor (36%) and the third (14%) factor among these factors. In contrast, 
pure unit price was a negative factor (declined 10%) with respect to drug expen-
ditures. ConClusions: The selection of more innovative/more expensive drugs 
over older/less expensive therapies dominated drug expenditure growth. Inpatient 
admission patterns and clinical prescription behavior should be a focus of drug 
spending controls. Health providers, insurance agencies, and policy makers can use 
these data to systematically intervene in health care service improvements instead 
of solely focusing on drug price regulations.
INfEctIous dIsEasE outcomEs rEsEarcH studIEs
IN1
comParatIVE safEty aNd EffIcacy of focusEd ultrasouNd for 
cErVIcal EctoPy: a mEta aNalysEs WItH 16180 PatIENts
Tang X, Yu J, Li Y, Li X
West China Hospital, Sichuan University, Chengdu, China
bACkgRound: Sexually transmitted infections(STIs) are serious public health prob-
lems and lead to tremendous burden of health and economy worldwide(account 
for 17% of economic loss caused by diseases in developing countries). Cervical 
ectopy is a common risk factor of STIs(including HIV and human papilloma virus 
infections), especially in developing countries. objeCtives: To assess the com-
parative safety and effectiveness of focused ultrasound(FU) and microwave(MW) 
for cervical ectopy. Methods: We searched Chinese Biomedical Literature data-
base (CBM), the Chinese Scientific Journals database (VIP),the China Academic 
Journals Full-text database (CNKI), MEDLINE, EMBASE, and Cochrane Library 
to July 31, 2013. Randomized controlled trials(RCTs) or clinical controlled 
trials(CCTs) were included. Two reviewers independently screened for eligi-
ble studies, extracted data and assessed risk of bias. We assessed the quality of 
included studies using criteria from Cochrane Handbook 5.0.Statistical analysis 
was performed by RevMan 5.02 , a random-effect model was used in this meta-
analysis. Funnel plots and Egger’s regression analyses were used to evaluate 
the publication bias. We used GRADE to summarize the results. Results: We 
included 26 RCTs(n= 10058) and 13 CCTs(n= 6122) both with high risk of bias. 
Meta-analyses indicated: compared with MW: FU reduced the risk of vaginal bleed 
(RCTs:RR= 0.12,95%CI [0.05-0.29]; CCTs:RR= 0.15,95%CI [0.09-0.25]) and vaginal dis-
charge (RCTs:RR= 0.30,95%CI [0.19-0.47];CCTs:RR= 0.45,95%CI [0.25-0.82]); increased 
cure rate (RCTs;RR= 1.07,95%CI [1.02-1.13];CCTs:RR= 1.16,95%CI [1.01-1.32]) and total 
effective rate (RCTs:RR= 1.04,95%CI [1.02-1.07];CCTs:RR= 1.07,95%CI [0.96-1.20]); 
decreased recurrence rate (RCTs;RR= 0.06,95%CI [0.01-0.45];CCTs:RR= 0.11,95%CI 
[0.02-0.67]). Egger’s regression analyses and funnel plots suggested likely publica-
tion bias in the safety studies. All safety and effective indicators were very low qual-
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Stroke in China (TIMS-China) study. Efficacy data were derived from a pooled analy-
sis of ECASS, ATLANTIS, NINDS, and EPITHET trials. Costs and quality-adjusted life-
years (QALYs) were compared both in short term (2 years) and in long term (30 years). 
One-way and probabilistic sensitivity analyses were performed to test the robust-
ness of the results. Results: Comparing to no tPA treatment, tPA treatment within 
4.5 hours has a gain of 0.101 QALYs at an additional cost of CNY 9,520 (US$ 1,460), 
yielding an incremental cost-effectiveness ratio (ICER) of CNY 94,300 (US$ 14,500) 
per QALY gained after 2 years, and a lifetime gain of 0.422 QALYs at an additional 
cost of CNY 6,530 (US$ 1,000), yielding an ICER of CNY 15,500 (US$ 2,380) per QALY 
gained. Probabilistic sensitivity analysis shows that tPA treatment is cost-effective 
in 98.7% of the simulations at a willingness-to-pay threshold of CNY 105,000 (US$ 
16,200) per QALY. ConClusions: Intravenous tPA treatment within 4.5 hours is 
highly cost-effective for acute ischemic stroke in China setting.
Qa4
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objeCtives: Lung cancer, especially non-small cell lung cancer (NSCLC), is one 
of the most leading causes of mortality not only in the world but also in Vietnam. 
Bevacizumab – a targeted therapy agent- has been recommended to use in combina-
tion with chemotherapy as the first-line treatment of advanced NSCLC. However, the 
high cost of bevacizumab may reduce the availability of bevacizumab, especially in 
Vietnam. Therefore, this analysis was conducted to analyze the cost-effectiveness 
of bevacizumab in the combination with paclitaxel and carboplatin (BCP) versus 
paclitaxel and carboplatin regimen (PC) in Vietnamese setting. Methods: A Markov 
model has been developed with 3 stages (stable, progressive and death). The model 
has a cycle length of 1 year with the life-time horizon. The population of 1000 
patients was included in the  model. The transition rates have been retrieved from 
randomized clinical trials, the prices of drugs and medical services have been aver-
aged from the price-lists of some major hospitals in Vietnam in 2013. The sensitiv-
ity analysis has been conducted. Results: The cost of BCP and PC regimen for 
NSCLC treatment accounts for 4,691,452,387 VND and 1,792,656,298 VND with the 
QALY of 7.88 and 5.62, respectively. The CER of BCP regimen for NCSLC treatment 
accounts for 595,533,261 VND, which is around 2 times higher than that of PC regi-
men. The ICER of BCP regimen versus PC regimen accounts for around 1.3 billion 
VND, which is about 17 times higher than the willingness-to-pay of Vietnam (74 
million VND). One-way sensitive analysis showed bevacizumab price as the most 
affecting factor on its cost-effectiveness. ConClusions: Due to the high cost of 
drug, the combination of bevacizumab in the PC regimen in treatment of NSCLC 
is considered not cost-effective in Vietnam. To enhance the cost-effectiveness of 
bevacizumab, supporting policies from manufacturer, health care providers and 
government should be established.
rEsPIratory – related disorders outcomes research studies
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objeCtives:  To evaluate physician’s knowledge and adherence to asthma guideline 
adherence (GINA 2011) at emergency department of Hospital Pulau Pinang, Malaysia 
and to calculate cost of adhered and non-adhered prescriptions. Methods: 
A cross-sectional survey was conducted to evaluate knowledge of GINA, 2011 asthma 
guideline at emergency department of Hospital Pulau Pinang, Malaysia. A total of 
810 patient prescriptions of 27 doctors (30 prescriptions per doctor) were viewed 
to asses doctor’s guideline adherence. Patients’ prescriptions were categorised in 
terms of asthma severity as mild, moderate and severe. Prescriptions were labelled 
as adhered or non-adhered in terms of doctor treatment according to patient 
asthma severity as recommended by CPG (GINA 2011). Cost of adhered and non-
adhered was calculated according to asthma severity. Results: Twenty two (81.5%) 
doctor’s had adequate GINA, 2011 asthma guideline knowledge (Mean 16.7, SD ± 
1.5). Six hundred and twenty eight (77.5%) patients received guideline (GINA 2011) 
adhered pharmacotherapy. Six hundred and seventy eight (83.7%) patients asthma 
were classified as mild asthma, 128 (15.8%) patients were classified as moderate 
asthma and 4 (0.5%) patients were classified as severe asthma. Pearson correlation 
indicated no statistical significant association between asthma guideline adher-
ence and asthma guideline knowledge score (p= 0.27). Univariate analysis indicate 
that patients with age group 25-35 years and with hypertension as co-morbidity 
received significantly better pharmacotherapy (p= 0.04, p= 0.03 respectively). Total 
cost of 628 adhered prescriptions was RM 5792.87 whereas cost of 182 non-adhered 
prescriptions was RM 1759.09. Cost of single mild asthma adhered prescription 
(RM 9.18) was less as compared to non adhered mild asthma prescription (RM 
10.39). ConClusions: Emergency doctor’s had adequate GINA, 2011 asthma guide-
line knowledge. Majority of patients received GINA, 2011 asthma guideline adhered 
pharmacotherapy. Cost effective medication can significantly reduce socioeconomic 
burden related to asthma.
rr2
rEsourcE utIlIzatIoN PattErN aNd cost of tuBErculosIs trEatmENt 
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the usual clinic, medicines availability at the clinic in the community. Results: 
The average immunization propensity is 0.69 (7,668 of 11,114) with a mean value of 
0.57 for flu vaccine propensity. The upward trend over time in household income 
and percentage of residents in urban area indicate the rapid economic development 
and the urbanization in China from 2000 to 2006. Logit, probit, and longitudinal 
linear random effects regression analyses showed that maternal education level 
positively affects the immunization propensity for children aged ≤ 6 (p< 0.01) and for 
children aged 7-18 (p< 0.1). Other factor, such as the medical insurance, whether the 
individual resides in urban area and the needed medicines availability at the clinic, 
also had a significant impact on the immunization propensity for children and 
adolescents (p< 0.05). ConClusions: Maternal education positively affects chil-
dren’s immunization propensity, particularly for those children below 6 years of age.
Qaly – related studies
Qa1
comParIsoN of tHE PrEfErENcE-BasEd EQ-5d aNd sf-6d HEaltH INdIcEs 
IN multIEtHNIc asIaN PatIENts WItH ENd-stagE rENal dIsEasE (Esrd)
Yang F.1, Lau T.2, Lee E.2, Vathsala A.2, Chia K.S.1, Luo N.1
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objeCtives: The purpose of this study was to compare the performance of 
the EuroQol 5-dimension (EQ-5D-5L) and the Short Form 6-dimension (SF-6D) 
instruments in assessing Asian patients with end-stage renal disease (ESRD) in 
Singapore. Methods: In a cross-sectional study, we interviewed ESRD patients 
who were dialyzed or followed up at the National University Hospital using a battery 
of questionnaires including the EQ-5D-5L, the kidney disease quality of life instru-
ment (KDQOL-36), and questions assessing dialysis history and socio-demographic 
characteristics. We reviewed patients’ medical records for their clinical information. 
We assessed the construct validity of the EQ-5D-5L and SF-6D index scores and 
compared their ability to distinguish between patients in differing health status 
and the magnitude of between-group difference they quantified. Results: One 
hundred and fifty ESRD patients on dialysis (mean age: 60.1 years; female: 48.7%) 
participated in the study. Both EQ-5D-5L and SF-6D demonstrated good known-
groups construct validity; the EQ-5D-5L was more sensitive to differences in clinical 
outcomes and the SF-6D was more sensitive to differences in KDQOL scales. The 
intraclass correlation coefficient between the measures was 0.36. The differences 
in (both actual and derived) EQ-5D index score for patients in better and worse 
health status were greater than those in SF-6D index score. ConClusions: Both 
EQ-5D-5L and SF-6D are valid instruments for assessing ESRD patients. However, 
the two preference-based health index scores cannot be used interchangeably and 
it appears that EQ-5D-5L would lead to more favorable cost-effectiveness results 
than SF-6D if they are used in economic evaluations of interventions for ESRD.
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structurEs IN taIWaN
Stewart G.1, Brooks-Rooney C.2
1Costello Medical Consulting Ltd., Cambridge, UK, 2Costello Medical Singapore Pte Ltd., Singapore
objeCtives: HTA in Taiwan was established in December 2007 to inform decision 
making on drug approvals and reimbursement prices. Drug categories were estab-
lished based on the therapeutic value and the innovative nature of new drugs, and 
various pricing structures were adopted. Price adjustments based on demonstra-
tive improvements in clinical efficacy and safety are also able to be applied. These 
adjustments can take into account clinical and pharmacoeconomic data specifically 
relevant to Taiwan. The aim of this study was to investigate the reimbursements of 
new health technologies assessed by the NIHTA with respect to drug categorisation, 
pricing structures and applied price adjustments. Methods: NIHTA assessment 
reports from 2011 to February 2014 were reviewed, and approval and pricing deci-
sions by the NHIA were evaluated. Results: Of the 52 assessments included in this 
analysis, 37 were approved for use on the National Health Insurance (NHI) in Taiwan. 
Of these, 57% were determined as having a comparable therapeutic value to the 
current best competitor, 38% were deemed to show moderate improvements and 
5% were considered breakthrough innovations. In most instances (73%), drugs were 
priced based on existing therapies. Of the approved health technologies, 9 (24%) were 
eligible for additional price adjustments. These were spread across multiple disease 
areas and reflected improved clinical and safety outcomes, dosing convenience and 
the availability of local clinical and economic data. The incidence of price adjust-
ments has increased in recent years, which is particularly evident with respect to high 
quality pharmacoeconomic data. ConClusions: The majority of drugs approved by 
the NHIA offer similar clinical benefit to current competitors and are priced based 
on existing therapies. Alternative methods involved calculating drug prices based 
on international reference countries, although manufacturers seem to be increas-
ingly seeking available price adjustments to achieve a higher price for their product.
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objeCtives: Previous economic studies conducted in developed countries showed 
intravenous tissue-type plasminogen activator (tPA) is cost-effective for acute 
ischemic stroke. This study aims to determine the cost-effectiveness of tPA treat-
ment in China setting. Methods: A combination of a decision tree and a Markov 
model was developed to determine the cost-effectiveness of tPA treatment versus 
no tPA treatment within 4.5 hours after stroke onset. Outcomes and costs data 
were derived from the Thrombolysis Implementation and Monitor of acute ischemic 
